OBJECTIVE： To investigate clinical efficacy and safety of meglumine adenosine cyclophosphate in the treatment of acute myocardium infarction. METHODS： A total of 80 patients with acute myocardium infarction in our hospital during May 2015-Jan. 2016 were selected and divided into control group and observation group according to random number table， 40 cases in each group. Control group was given conventional treatment. Observation group was additionally given Meglumine adenosine cyclophosphate injection 120 mg added into 5％ Glucose injection 250 mL， ivgtt， qd， on the basis of control group. Both groups received treatment for 7 d. Clinical efficacies as well as the levels of serum hs-CRP and NT-proBNP before and after treatment were observed in 2 groups， and the occurrence of ADR was compared between 2 groups. RESULTS： Total response rate of observation group （92.50％） was significantly higher than that of control group （75.00％）， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in the serum levels of hs-CRP or NT-proBNP between 2 groups （P＞0.05）. After treatment， the serum levels of hs-CRP and NT-proBNP in 2 groups were decreased significantly， and the observation group was significantly lower than the control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Meglumine adenosine cyclophosphate shows significant therapeutic efficacy for acute myocardium infarction， reduces serum levels of hs-CRP and NT-proBNP significantly with good safety.